Display options
Cite
Soleimani M, Mirmohammmad Sadeghi H, Jahanian-Najafabadi A. A Bi-Functional Targeted P28-NRC Chimeric Protein with Enhanced Cytotoxic Effects on Breast Cancer Cell Lines. Iran J Pharm Res. 2019;18(2):735-744doi: 10.22037/ijpr.2019.2392.
Soleimani, M., Mirmohammmad Sadeghi, H., & Jahanian-Najafabadi, A. (2019). A Bi-Functional Targeted P28-NRC Chimeric Protein with Enhanced Cytotoxic Effects on Breast Cancer Cell Lines. Iranian journal of pharmaceutical research : IJPR, 18(2), 735-744. https://doi.org/10.22037/ijpr.2019.2392
Soleimani, Meysam, et al. "A Bi-Functional Targeted P28-NRC Chimeric Protein with Enhanced Cytotoxic Effects on Breast Cancer Cell Lines." Iranian journal of pharmaceutical research : IJPR vol. 18,2 (2019): 735-744. doi: https://doi.org/10.22037/ijpr.2019.2392
Soleimani M, Mirmohammmad Sadeghi H, Jahanian-Najafabadi A. A Bi-Functional Targeted P28-NRC Chimeric Protein with Enhanced Cytotoxic Effects on Breast Cancer Cell Lines. Iran J Pharm Res. 2019;18(2):735-744. doi: 10.22037/ijpr.2019.2392. PMID: 31531057; PMCID: PMC6706745.
Copy Download .nbib Format: NLM
Share it on

Iran J Pharm Res. 2019;18(2):735-744. doi: 10.22037/ijpr.2019.2392.

A Bi-Functional Targeted P28-NRC Chimeric Protein with Enhanced Cytotoxic Effects on Breast Cancer Cell Lines.

Iranian journal of pharmaceutical research : IJPR

Meysam Soleimani, Hamid Mirmohammmad Sadeghi, Ali Jahanian-Najafabadi

Affiliations

  1. Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
  2. Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
  3. Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

PMID: 31531057 PMCID: PMC6706745 DOI: 10.22037/ijpr.2019.2392

Abstract

One of the emerging therapeutic strategies for targeted therapy of cancer is the use of chimeric proteins. The p28 peptide has the ability of selective entrance and activating apoptosis in breast cancer cells. The NRC antimicrobial peptide showed cytotoxic activity on various breast cancer cell lines including drug-resistant cells and also on normal cells. Here we designed a chimeric protein consisting of these peptides to determine their targeted effects and to enhance their cytotoxic effects on breast cancer cells. The chimeric protein was cytotoxic to MDA-MB-231 and MCF7 breast cancer cell lines in a dose-dependent manner after 48 h of treatment. In addition, the cytotoxic effects of the p28 alone were significantly lower than the chimeric protein indicating the additive or enhanced effects of the two peptides. Flow cytometry analysis showed that the induced cell death is mediated via apoptosis. The designed chimeric protein had enhanced effects on breast cancer cell lines and exerted its anticancer effects on MCF7 breast cancer cells through mitochondrial caspase dependent and -independent apoptotic pathways. Taken together, the results of this study suggested the chimeric protein to be a reasonable anti-cancer agent which must be further evaluated by subsequent

Keywords: Antimicrobial Cationic peptides; Azurin-p28; Breast Cancer; Chimeric proteins

References

  1. Crit Rev Toxicol. 2000 Sep;30(5):571-94 - PubMed
  2. Int J Cancer. 2002 Mar 20;98(3):323-30 - PubMed
  3. Biochimie. 2002 Feb-Mar;84(2-3):215-22 - PubMed
  4. Cancer Treat Rev. 2003 Dec;29(6):515-23 - PubMed
  5. Cancer Res. 2003 Dec 15;63(24):8890-8 - PubMed
  6. Breast Cancer Res Treat. 2003 Dec;82(3):199-206 - PubMed
  7. Oncogene. 2004 Mar 25;23(13):2367-78 - PubMed
  8. Methods Mol Med. 2005;111:127-48 - PubMed
  9. Mol Cell Endocrinol. 2007 Jan 2;260-262:183-9 - PubMed
  10. Cancer Res. 2009 Jan 15;69(2):537-46 - PubMed
  11. Protein Expr Purif. 2010 Oct;73(2):147-51 - PubMed
  12. Cancer Chemother Pharmacol. 2011 Aug;68(2):513-24 - PubMed
  13. Breast Cancer Res. 2011 Oct 24;13(5):R102 - PubMed
  14. J Amino Acids. 2012;2012:967347 - PubMed
  15. Cancer Lett. 2014 Aug 28;351(1):13-22 - PubMed
  16. Evid Based Complement Alternat Med. 2014;2014:639856 - PubMed
  17. Cancer Cell Int. 2015 Jul 15;15:71 - PubMed
  18. Adv Biomed Res. 2016 Apr 19;5:70 - PubMed
  19. Res Pharm Sci. 2016 May-Jun;11(3):187-99 - PubMed
  20. J Microbiol Methods. 2016 Nov;130:100-105 - PubMed
  21. Acta Pharmacol Sin. 2017 Jun;38(6):897-906 - PubMed
  22. Curr Protein Pept Sci. 2018;19(8):759-770 - PubMed

Publication Types